ACT.JSE AfroCentric Investment Corp
- Market cap
- ZAC 508M
- P/E
- -
- P/B
- 29.01x
- ROE
- -67.0%
- Dividend yield
- -
- Fundamental score
- 1.4/5
Ratios use the latest price and the fiscal year ending Jun 2026.
Is ACT.JSE undervalued?
Graham numberThe Graham number of AfroCentric Investment Corp cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
AfroCentric Investment Corp fundamental analysis
6 of 21 checks passedROE 0/2
Low return on equity (-67.0%), below 10%.
ROA 0/1
Return on assets (-30.5%) is below the industry median (5.9%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share did not grow over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Last year's EPS growth (-4,135.5%) is below the industry median (-19.9%).
Revenue Growth 0/2
Revenue shrank 5.9% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (39.1%), 40% or less.
Debt Trend 1/1
Debt to equity has not risen over the past 5 years.
Cash Runway 2/2
Loss-making but free cash flow is positive.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 1/1
Price to book (0.3x) is below the industry median (1.4x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
AfroCentric Investment Corp stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About AfroCentric Investment Corp
AfroCentric Investment Corporation Limited, an investment holding company, provides healthcare products and services to private and public sectors in South Africa and internationally. The company operates through Healthcare SA, Healthcare Retail, Healthcare Africa, and Information Technology segments. It offers health administration, health risk management, medical scheme administration, marketing and distribution, as well as specialized and technology-based products and ser…
Full company profileAfroCentric Investment Corp financial statements
AfroCentric Investment Corp annual financial statements (ZAR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 3.78B | 4.21B | 5.30B | 6.44B | 8.07B | 8.72B | 8.76B | 8.79B | 8.50B | 7.30B |
| Gross Profit | 2.85B | 3.23B | 3.90B | 4.93B | 3.55B | 6.45B | 4.78B | 3.65B | 4.94B | 4.78B |
| Operating Income | 367M | 623M | 464M | 663M | 775M | 734M | 3.64B | 550M | 675M | 159M |
| EBITDA | 485M | 657M | 812M | 984M | 1.09B | 1.13B | 865M | 652M | 567M | -63.8M |
| Net Income | 118M | 257M | 270M | 304M | 302M | 313M | 184M | 55.4M | -28.8M | -1.27B |
| EPS | 0.21 | 0.46 | 0.47 | 0.52 | 0.51 | 0.53 | 0.30 | 0.07 | -0.04 | -1.49 |
| Balance Sheet | ||||||||||
| Total Assets | 3.07B | 3.13B | 4.45B | 4.55B | 5.11B | 5.44B | 5.56B | 5.41B | 5.16B | 4.18B |
| Total Liabilities | 690M | 510M | 1.57B | 1.43B | 1.86B | 1.99B | 2.06B | 2.01B | 1.88B | 2.24B |
| Shareholders' Equity | 1.79B | 1.94B | 2.10B | 2.22B | 2.33B | 2.45B | 3.44B | 3.37B | 3.25B | 1.90B |
| Cash & Short-term Investments | 709M | 365M | 265M | 178M | 199M | 139M | 190M | 330M | 357M | 637M |
| Total Debt | 19.0M | 15.9M | 814M | 665M | 996M | 850M | 996M | 805M | 791M | 744M |
| Cash Flow | ||||||||||
| Operating Cash Flow | 205M | 291M | 307M | 502M | 385M | 527M | 382M | 814M | 548M | 685M |
| Capital Expenditure | 250M | 525M | 341M | 421M | 494M | 304M | 258M | 262M | 253M | 219M |
| Free Cash Flow | -44.4M | -234M | -33.8M | 80.5M | -109M | 223M | 123M | 433M | 295M | 466M |
| Ratios | ||||||||||
| ROE | 6.6% | 13.2% | 12.9% | 13.7% | 13.0% | 12.8% | 5.3% | 1.6% | -0.9% | -67.0% |
| ROA | 3.8% | 8.2% | 6.1% | 6.7% | 5.9% | 5.8% | 3.3% | 1.0% | -0.6% | -30.5% |
| Net Profit Margin | 3.1% | 6.1% | 5.1% | 4.7% | 3.7% | 3.6% | 2.1% | 0.6% | -0.3% | -17.4% |
| Debt to Equity | 0.01x | 0.01x | 0.39x | 0.30x | 0.43x | 0.35x | 0.29x | 0.24x | 0.24x | 0.39x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
AfroCentric Investment Corp dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- May 7, 2025
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | - | - | - |
| 2025 | ZAR 4.55M | 0.01 | - |
| 2024 | ZAR 119M | 0.14 | 215.1% |
| 2023 | ZAR 164M | 0.27 | 89.3% |
| 2022 | ZAR 294M | 0.50 | 94.0% |
| 2021 | ZAR 328M | 0.56 | 108.5% |
| 2020 | ZAR 239M | 0.41 | 78.8% |
| 2019 | ZAR 186M | 0.33 | 69.0% |
| 2018 | ZAR 166M | 0.30 | 64.8% |
| 2017 | ZAR 144M | 0.26 | 122.5% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 49211:9022 on Jul 17, 2006.
Who owns AfroCentric Investment Corp
- Insiders 88.46%
- Institutions 9.04%
- Public & others 2.50%
- Shares outstanding 819M
- Free float 27.5M
AfroCentric Investment Corp company profile
- Company name
- AfroCentric Investment Corp
- Ticker
- ACT.JSE
- ISIN
- ZAE000078416
- Exchange
- Johannesburg Exchange
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Fiscal year end
- June
- Address
- 37 Conrad Road, Roodepoort, South Africa, 1709
- Phone
- 27 11 671 2000
- Website
- afrocentric.za.com
About AfroCentric Investment Corp
AfroCentric Investment Corporation Limited, an investment holding company, provides healthcare products and services to private and public sectors in South Africa and internationally. The company operates through Healthcare SA, Healthcare Retail, Healthcare Africa, and Information Technology segments. It offers health administration, health risk management, medical scheme administration, marketing and distribution, as well as specialized and technology-based products and services; HIV/AIDS management; DBC equipment and administration services to musculoskeletal treatment centres; and dental management services. The company also engages in the manufacture, distribution, marketing, and retail of medicines and pharmaceutical products under the Pharmacy Direct, Curasana, Activo Health, and Scriptpharm brand names. In addition, it provides health insurance products for individuals and organisations; occupational health programmes; administration services for a market of medical schemes, health insurers and corporate clients; wellness programmes, including health risk assessments, corporate nursing, lifestyle initiatives, executive wellness, and employee assistance programmes; chronic condition monitoring, referrals, health education and emergency services; and gap cover, a short-term insurance product that offers additional financial protection to medical aid members. The company was incorporated in 1988 and is based in Roodepoort, South Africa. AfroCentric Investment Corporation Limited is a subsidiary of Sanlam Life Insurance Limited.
AfroCentric Investment Corp management
6- Mr. Gerald N. Van WykGroup CEO & Director
- Mr. K. Thato MoloeleCFO & Executive Director
- Mr. Monwabisi KulaChief Risk Officer
- Mr. Satish AntonyChief Analytics & Strategy Officer
- Mr. Jeremy YattChief Growth Officer
- Ms. Lebohang MpumlwanaGroup Company Secretary · born 1985